$192 Million is the total value of AH Equity Partners Bio II, L.L.C.'s 4 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | EQRx, Inc. | $118,930,000 | – | 17,438,465 | +100.0% | 61.93% | – | |
New | Erasca, Inc. | $38,950,000 | – | 2,500,000 | +100.0% | 20.28% | – | |
NVTA | New | InVitae Corporation | $17,868,000 | – | 1,170,127 | +100.0% | 9.30% | – |
NAUT | New | Nautilus Biotechnology, Inc. | $16,298,000 | – | 16,298,006 | +100.0% | 8.49% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
EQRx, Inc. | 4 | Q3 2022 | 61.9% |
Nautilus Biotechnology, Inc. | 4 | Q3 2022 | 40.8% |
Erasca, Inc. | 4 | Q3 2022 | 20.3% |
InVitae Corporation | 4 | Q3 2022 | 9.3% |
View AH Equity Partners Bio II, L.L.C.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2023-11-09 |
4 | 2023-01-04 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
3 | 2021-12-22 |
3 | 2021-06-09 |
View AH Equity Partners Bio II, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.